Folic Acid Supplementation for Stroke Prevention in Patients With Cardiovascular Disease

American Journal of the Medical Sciences

Volumn 354, Issue 4, 2017, Pages 379-387

  Tian, Tao ^a   Yang, Kun Qi ^a   Cui, Jin Gang ^a   Zhou, Lan Lan ^b   Zhou, Xian Liang ^a  

^a FUWAI HOSPITAL   (China)

^b Intensive Care Unit   (China)

Author keywords

Cardiovascular disease; Folic acid; Homocysteine; Meta analysis; Stroke

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE; VITAMIN B GROUP;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG EFFICACY; FORTIFIED FOOD; GRAIN; HUMAN; LOW DRUG DOSE; META ANALYSIS; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; AGED; BIOLOGICAL MODEL; DIETARY SUPPLEMENT; FEMALE; MALE; MIDDLE AGED; RISK FACTOR; STROKE;

AGED; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 85032691322     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1016/j.amjms.2017.05.020     Document Type: Article

References (50)

1. Hunter, D.J., Reddy, K.S., Noncommunicable diseases. N Engl J Med 369 (2013), 1336–1343.
2. Meschia, J.F., Bushnell, C., Boden-Albala, B., et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45 (2014), 3754–3832.
3. Wald, D.S., Law, M., Morris, J.K., Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J, 325, 2002, 1202.
4. Homocysteine Studies, C., Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 288 (2002), 2015–2022.
5. Wald, D.S., Wald, N.J., Morris, J.K., et al. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. Br Med J 333 (2006), 1114–1117.
6. Mujumdar, V.S., Aru, G.M., Tyagi, S.C., Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem 82 (2001), 491–500.
7. Pang, X., Liu, J., Zhao, J., et al. Homocysteine induces the expression of C-reactive protein via NMDAr-ROS-MAPK-NF-kappaB signal pathway in rat vascular smooth muscle cells. Atherosclerosis 236 (2014), 73–81.
8. Abbenhardt, C., Miller, J.W., Song, X., et al. Biomarkers of one-carbon metabolism are associated with biomarkers of inflammation in women. J Nutr 144 (2014), 714–721.
9. Zhang, D., Chen, Y., Xie, X., et al. Homocysteine activates vascular smooth muscle cells by DNA demethylation of platelet-derived growth factor in endothelial cells. J Mol Cell Cardiol 53 (2012), 487–496.
10. Wilcken, D.E., Wilcken, B., The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 57 (1976), 1079–1082.
11. Clarke, R., Daly, L., Robinson, K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 (1991), 1149–1155.
12. Verhoef, P., Meleady, R., Daly, L.E., et al. Homocysteine, vitamin status and risk of vascular disease; effects of gender and menopausal status. European COMAC Group. Eur Heart J 20 (1999), 1234–1244.
13. Knekt, P., Alfthan, G., Aromaa, A., et al. Homocysteine and major coronary events: a prospective population study amongst women. J Intern Med 249 (2001), 461–465.
14. Homocysteine Lowering Trialists, C., Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 82 (2005), 806–812.
15. McCully, K.S., Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 86 (2007), 1563S–1568SS.
16. Yang, Q., Botto, L.D., Erickson, J.D., et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113 (2006), 1335–1343.
17. Lonn, E., Yusuf, S., Arnold, M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006), 1567–1577.
18. Galan, P., Kesse-Guyot, E., Czernichow, S., et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. Br Med J, 341, 2010, c6273.
19. Armitage, J.M., Bowman, L., Clarke, R.J., et al., Study of the Effectiveness of Additional Reductions in Cholesterol and, Homocysteine Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. J Am Med Assoc 303 (2010), 2486–2494.
20. Group, V.T.S., B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 9 (2010), 855–865.
21. Ebbing, M., Bleie, O., Ueland, P.M., et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. J Am Med Assoc 300 (2008), 795–804.
22. Albert, C.M., Cook, N.R., Gaziano, J.M., et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. J Am Med Assoc 299 (2008), 2027–2036.
23. Zhang, C., Chi, F.L., Xie, T.H., et al. Effect of B-vitamin supplementation on stroke: a meta-analysis of randomized controlled trials. PLoS One, 8, 2013, e81577.
24. Clarke, R., Halsey, J., Lewington, S., et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 170 (2010), 1622–1631.
25. Wang, X., Qin, X., Demirtas, H., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369 (2007), 1876–1882.
26. Ji, Y., Tan, S., Xu, Y., et al. Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: a meta-analysis. Neurology 81 (2013), 1298–1307.
27. Juni, P., Altman, D.G., Egger, M., Systematic reviews in health care: assessing the quality of controlled clinical trials. Br Med J 323 (2001), 42–46.
28. Collaboration C Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. 0. Updated March 2011.
29. Greenland, S., Robins, J.M., Estimation of a common effect parameter from sparse follow-up data. Biometrics 41 (1985), 55–68.
30. Mantel, N., Haenszel, W., Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959), 719–748.
31. Toole, J.F., Malinow, M.R., Chambless, L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. J Am Med Assoc 291 (2004), 565–575.
32. Bonaa, K.H., Njolstad, I., Ueland, P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006), 1578–1588.
33. Liem, A.H., van Boven, A.J., Veeger, N.J., et al. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol 93 (2004), 175–179.
34. Liem, A., Reynierse-Buitenwerf, G.H., Zwinderman, A.H., et al. Secondary prevention with folic acid: results of the Goes extension study. Heart 91 (2005), 1213–1214.
35. Lee, M., Hong, K.S., Chang, S.C., et al. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke 41 (2010), 1205–1212.
36. Brattstrom, L., Vitamins as homocysteine-lowering agents. J Nutr 126 (1996), 1276S–1280SS.
37. Shirodaria, C., Antoniades, C., Lee, J., et al. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation 115 (2007), 2262–2270.
38. Antoniades, C., Antonopoulos, A.S., Tousoulis, D., et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 30 (2009), 6–15.
39. Mittermayer, F., Krzyzanowska, K., Exner, M., et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 26 (2006), 2536–2540.
40. Loscalzo, J., Homocysteine trials—clear outcomes for complex reasons. N Engl J Med 354 (2006), 1629–1632.
41. Spence, J.D., Nutrition and stroke prevention. Stroke 37 (2006), 2430–2435.
42. Spence, J.D., Bang, H., Chambless, L.E., et al. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 36 (2005), 2404–2409.
43. Huo, Y., Qin, X., Wang, J., et al. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis. Int J Clin Pract 66 (2012), 544–551.
44. de Bree, A., Verschuren, W.M., Bjorke-Monsen, A.L., et al. Effect of the methylenetetrahydrofolate reductase 677C—>T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr 77 (2003), 687–693.
45. Chiuve, S.E., Giovannucci, E.L., Hankinson, S.E., et al. Alcohol intake and methylenetetrahydrofolate reductase polymorphism modify the relation of folate intake to plasma homocysteine. Am J Clin Nutr 82 (2005), 155–162.
46. Hustad, S., Midttun, O., Schneede, J., et al. The methylenetetrahydrofolate reductase 677C—>T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. Am J Hum Genet 80 (2007), 846–855.
47. Holmes, M.V., Newcombe, P., Hubacek, J.A., et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 378 (2011), 584–594.
48. Huo, Y., Li, J., Qin, X., et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. J Am Med Assoc 313 (2015), 1325–1335.
49. Saposnik, G., Ray, J.G., Sheridan, P., et al. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 40 (2009), 1365–1372.
50. Hankey, G.J., Eikelboom, J.W., Yi, Q., et al. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol 11 (2012), 512–520.